ADIL: Total Utang marang Modal Adial Pharmaceuticals

Adial Pharmaceuticals - logo grafis emiten ADIL

The development of methods to combat alcoholism is independent of market cycles, creating a stable foundation for Adial Pharmaceuticals (ADIL). A lack of proprietary sales makes the company dependent on investments, and the individual debt-to-equity ratio stands at 0.00. The price action of this parameter coincides with data regarding strategic alliances with clinics and the acquisition of relevant patents to advance the AD04 molecule.

Adial Pharmaceuticals Inc. (ADIL): Rasio Kabeh Utang marang Dana Pribadi saka 04.07.2022 nganti 29.10.2026

Rincian metrik lan analitis perusahaan Adial Pharmaceuticals, Inc. (ADIL)

- rega lan prakiraan konsensus rega:
Bagan rega Adial Pharmaceuticals Inc.|ADIL - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Adial Pharmaceuticals|ADIL - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Adial Pharmaceuticals|ADIL - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku adialpharma.com|ADIL - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Utang marang Ekuitas Adial Pharmaceuticals|ADIL - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Adial Pharmaceuticals Inc.|ADIL - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Adial Pharmaceuticals|ADIL - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Adial Pharmaceuticals|Likuiditas cepet adialpharma.com
- data bathi resik lan rasio valuasi:
ADIL - Bathi pungkasan
Pambiji fundamental perusahaan:Adial Pharmaceuticals, ADIL
Barang utama Adial

For investors in Adial Pharmaceuticals (ADIL), it is critical to weigh market expectations against the binary risks of a single-product pipeline, where financial stability depends directly on external funding. By analyzing the history of the debt-to-equity ratio, we assess the ratio of total liabilities to equity, which allows us to determine the business's degree of credit dependence and its ability to operate in the absence of operating revenue.

Karo sapa Adial Pharmaceuticals saingan

Utang marang Ekuitas Indivior|Rasio Utang marang Ekuitas COLL (Collegium Pharma)|Total Utang marang Modal CRON|Total Utang marang Modal Canopy Growth Corp. (CGC)|Utang marang Ekuitas High Tide Inc. HITI|Rasio Kabeh Utang marang Dana Pribadi ACB|Achieve Life Sciences, Inc. - Total Utang marang Modal|Skye Bioscience Inc. (SKYE) - Rasio Total Utang marang Ekuitas|Anebulo (ANEB) - Utang marang Ekuitas|Utang marang Modal InterCure (INCR)|Rasio Total Utang marang Ekuitas NTRB|NSRX: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal IGC|MIRA: Utang Agregat marang Ekuitas|Total Utang marang Modal FLGC (Flora Growth Corporation)|Total Utang marang Modal IM Cannabis Corp IMCC|ARTL - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ENSC (Ensysce Biosciences)|titanpharm.com (TTNP) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Greenlane Holdings, Inc.|INM (InMed Pharma) - Total Utang marang Modal|Total Utang marang Modal Akanda Inc|Total Utang marang Modal ENVB|brightgreen.us - Rasio Utang marang Ekuitas|Total Utang marang Modal HPCO (Hempacco Co., Inc.)